IL-21 comes of age as a regulator of effector T cells in the gut

Mucosal Immunology

Volumn 1, Issue 2, 2008, Pages 110-115

  Fantini, M C ^a   Monteleone, G ^a   MacDonald, T T ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOTAXIS; CROHN DISEASE; DRUG TARGETING; EFFECTOR CELL; ENTERITIS; ENZYME DEGRADATION; ENZYME RELEASE; EPITHELIUM CELL; FIBROBLAST; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; INTESTINE CELL; INTESTINE FLORA; INTESTINE INJURY; INTESTINE MUCOSA; LYMPHOCYTE DIFFERENTIATION; MOLECULAR INTERACTION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; ULCERATIVE COLITIS;

EID: 48849104250     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2007.17     Document Type: Review

References (49)

1. van Assche, G. Emerging drugs to treat Crohn's disease. Expert Opin. Emerg. Drugs 12, 49-59 (2007).
2. Mannon, P.J. et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079 (2004).
3. Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996 (2004).
4. Takahashi, I., Kiyono, H. & Hamada, S. CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor alpha chain-deficient mice. Gastroenterology 112, 1876-1886 (1997).
5. Sturm, A. et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 53, 1624-1631 (2004).
6. Ina, K. et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 163, 1081-1090 (1999).
7. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-688 (2000).
8. Parrish-Novak, J. et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57-63 (2000).
9. Monteleone, G. et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112, 1169-1178 (1997).
10. Neurath, M.F et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195, 1129-1143 (2002).
11. Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725 (2000).
12. Schmidt, C. et al. Expression of interlbuldn-12-related cytokine transcripts in inflammatory bowel disease: Elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11, 16-23 (2005).
13. Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218-1222 (2006).
14. Neurath, M.F., Fuss, I., Kelsall, B.L., Stuber, E. & Strober, W. Antibodies to interleukin 12 abrogate established experimental colitis in mice, J. Exp. Med. 182, 1281-1290 (1995).
15. Monteleone, G. et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128, 687-694 (2005).
16. Brandt, K., Butione-Paus, S., Foster, D.C. & Ruckert, R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102 4090-4098 (2003).
17. Brandt, K., Bulfone-Paus, S., Jenckel, A., Foster, D.C., Paus, R. & Ruckert, R. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J. Invest. Darmatol. 121, 1379-1382 (2003).
18. Distler, J.H. et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 52, 856-864 (2005).
19. Jin, H., Carrio, R., Yu, A. & Malek, TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173, 657-665 (2004).
20. Strengell, M., Jukunen, I. & Matikainen, S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J. Leukoc. Biol. 76, 416-422 (2004).
21. Zeng, R. et al. Synergy of IL-21 and L-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139-148 (2005).
22. Strengell, M., Sareneva, T, Foster, D., Julkunen, I. & Matikainen, S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169, 3600-3605 (2002).
23. Ozaki, K. et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630-1634 (2002).
24. Ozaki, K. et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173, 5361-5371 (2004).
25. Wurster, A.L. et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J. Exp. Med. 196, 969-977 (2002).
26. Suto, A., Wurster, A.L., Reiner, S.L. & Grusby, M.J. IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression. J. Immunol. 177, 3721-3727 (2006).
27. Pesce, J. et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116, 2044-2055 (2006).
28. Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121-1133 (2006).
29. Mangan, PR. et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231-234 (2006).
30. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
31. Chen, W. et al. Conversion of peripheral CD4+CD25 - naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
32. Fantini, M.C., Becker, C., Monteleone, G., Pallone, F., Galle, P.R. & Neurath, M.F Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25 - T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172, 5149-5153 (2004).
33. Dominitzki, S. et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J. Immunol. 179, 2041-2045 (2007).
34. Langrish, C.L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005).
35. Harrington, L.E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132 (2005).
36. Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116 1310-1316 (2006).
37. Elson, C.O. et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132, 2359-2370 (2007).
38. Becker, C. et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental, colitis. J. Immunol. 177, 2760-2764 (2006).
39. Fuss, I.J. et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12p40 monoclonal antibody. Inflamm. Bowel Dis. 12, 9-15 (2006).
40. Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65-70 (2003).
41. Duerr, R.H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
42. Zhou, L. et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 8, 967-974 (2007).
43. Korn, T. et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448, 484-487 (2007).
44. Nurieva, R. et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480-483 (2007).
45. Wei, L., Laurence, A., Elias, K. M. & O'Shea, J.J. IL-21 is produced by TH17 cells and drives L-17 production in a STAT3-dependent manner. J. Biol. Chem. 282, 34605-34610 (2007).
46. Fantini, M.C. et al. IL-21 regulates experimental colitis by modulaiting the balance between T(reg) and Th17 cells. Eur J. Immunol. 37, 3155-3163 (2007).
47. Caruso, R. et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 132, 166-175 (2007).
48. Annunziato, F. et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849-1861 (2007).
49. Monteleone, G. et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55, 1774-1780 (2006).